Investigational Drug Information for BAY2433334
✉ Email this page to a colleague
What is the drug development status for BAY2433334?
BAY2433334 is an investigational drug.
There have been 7 clinical trials for BAY2433334.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 16th 2023.
The most common disease conditions in clinical trials are Stroke, Ischemic Stroke, and Atrial Fibrillation. The leading clinical trial sponsors are Bayer, Population Health Research Institute, and [disabled in preview].
There are zero US patents protecting this investigational drug and zero international patents.
Summary for BAY2433334
| US Patents | 1,695 |
| International Patents | 17,311 |
| US Patent Applications | 2,553 |
| WIPO Patent Applications | 1,042 |
| Japanese Patent Applications | 1,024 |
| Clinical Trial Progress | Phase 2 (2023-02-16) |
| Vendors | 31 |
Recent Clinical Trials for BAY2433334
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled t | Bayer | Phase 3 |
| A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke | Bayer | Phase 3 |
| A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With No | Bayer | Phase 1 |
Clinical Trial Summary for BAY2433334
Top disease conditions for BAY2433334
Top clinical trial sponsors for BAY2433334
US Patents for BAY2433334
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BAY2433334 | ⤷ Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Start Trial |
| BAY2433334 | ⤷ Start Trial | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (Tokyo, JP) | ⤷ Start Trial |
| BAY2433334 | ⤷ Start Trial | 2,4-disubstituted pyrimidines useful as kinase inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| BAY2433334 | ⤷ Start Trial | Substituted spirocyclic inhibitors of autotaxin | X-RX Inc , Bioduro LLC | ⤷ Start Trial |
| BAY2433334 | ⤷ Start Trial | PPARG modulators for treatment of osteoporosis | University of Florida , University of Toledo , University of Florida Research Foundation Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BAY2433334
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BAY2433334 | Canada | CA2961033 | 2034-09-11 | ⤷ Start Trial |
| BAY2433334 | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Start Trial |
| BAY2433334 | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Start Trial |
| BAY2433334 | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | ⤷ Start Trial |
| BAY2433334 | Australia | AU2014338070 | 2033-10-23 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
